Growth hormone therapy in childhood-onset growth hormone deficiency: adult anthropometric and psychological outcomes.

摘要: The current adult heights of hypopituitary children treated with recombinant human growth hormone (rGH) now range between −1.5 and −0.7 height standard deviations (HtSDS) control populations. These outcomes are markedly better than the ones observed following treatment pituitary-derived (pGH) (between −4.7 −2.0 Ht SDS). Although rGH has not yielded that equal to genetic target heights, discrepancy is much less in previous decades. Higher dose, longer duration treatment, early age at diagnosis, correction deficit prior onset puberty, daily injections have had beneficial effects on final heights. dosing regimens, (0.3–0.18 mg/kg/wK) an adverse effect bone maturation stimulated earlier puberty. gains puberty controls, a majority subjects reach within normal for adults. doses during been studied limited numbers adolescents positive effects; however, will likely continue be used because financial considerations safety concerns. Further improvements reported when youngest who began 1985 complete their growth.